Nyxoah SA (Nyxoah), a pioneering medical technology firm, recently launched its innovative Genio system in England to address obstructive sleep apnoea (OSA) with neuromodulation techniques. This commercial introduction was celebrated with the initial successful procedures at University College London Hospitals (UCLH).
With the Genio system now included under the NHS Specialised Services Devices Programme (SSDP), patients can access these advanced therapies through specialized centers committed to offering excellence.
The first two patients benefitted from implants successfully carried out by Ryan Chin Taw Cheong, a distinguished consultant ENT and sleep surgeon at UCLH. In recognition of this achievement, Cheong remarked, “We are thrilled to be the pioneering UK hospital to provide Genio to those with OSA. Genio represents a revolutionary, clinically validated treatment that meets the pressing needs of individuals battling obstructive sleep apnoea.”
Olivier Taelman, Nyxoah’s CEO, remarked, “This day marks a pivotal achievement for Nyxoah as we roll out our Genio neurostimulation solution in England to manage obstructive sleep apnoea. Our heartfelt congratulations to Cheong and his dedicated team for this impressive accomplishment. We are eager to broaden our partnership with UCLH and other foremost hospitals across England as we strive to simplify sleep for those affected by OSA.”
Nyxoah is on a mission to transform sleep for the billion individuals afflicted with obstructive sleep apnoea (OSA). The firm specializes in cutting-edge medical technology, focusing its efforts on creating breakthrough neuromodulation treatments for OSA.